Immuneering Corp (IMRX) CMO granted stock options for 140,000 shares

Rhea-AI Filing Summary

Immuneering Corp’s Chief Medical Officer, Igor Matushansky, received a new stock option grant. On February 3, 2026, he was awarded options to acquire 140,000 shares of Class A common stock at an exercise price of $4.91 per share.

The options vest in equal monthly installments over four years starting February 1, 2026 and are scheduled to be fully vested and exercisable on January 1, 2030, aligning long-term compensation with the company’s future performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matushansky Igor

(Last) (First) (Middle)

C/O IMMUNEERING CORPORATION

245 MAIN STREET, SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.91	02/03/2026		A		140,000		(1)	02/03/2036	Class A Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Igor Matushansky	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Immuneering Corp (IMRX) report in this Form 4?

Immuneering Corp reported a stock option grant to Chief Medical Officer Igor Matushansky. He was awarded options on 140,000 shares of Class A common stock on February 3, 2026, as part of his equity-based compensation package.

How many Immuneering Corp (IMRX) shares are covered by the new stock options?

The new stock option grant covers 140,000 shares of Immuneering Corp Class A common stock. These options give the Chief Medical Officer the right to purchase that number of shares if and when he chooses to exercise them.

What is the exercise price of the Immuneering Corp (IMRX) stock options granted?

The stock options were granted with an exercise price of $4.91 per share. This price is the fixed amount the holder must pay per share to convert the options into Immuneering Class A common stock in the future.

How do the new Immuneering Corp (IMRX) options vest over time?

The options vest in equal monthly installments over four years, beginning February 1, 2026. According to the disclosure, they will be fully vested and exercisable by January 1, 2030, creating a long-term incentive structure for the executive.

Who received the Immuneering Corp (IMRX) stock option grant disclosed here?

The grant was made to Igor Matushansky, Immuneering Corp’s Chief Medical Officer. He is an officer of the company, and this award increases his derivative holdings through stock options linked to Class A common stock.

Is the Immuneering Corp (IMRX) option grant reported as directly owned?

Yes. The Form 4 lists the 140,000 stock options as directly owned by the reporting person. There is no indication in the footnotes that another entity holds the options or that beneficial ownership is disclaimed.